699 related articles for article (PubMed ID: 29494928)
1. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
2. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
3. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
4. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.
Miura M
Biol Pharm Bull; 2015; 38(5):645-54. PubMed ID: 25947908
[TBL] [Abstract][Full Text] [Related]
6. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
7. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
[No Abstract] [Full Text] [Related]
8. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Ota S; Matsukawa T; Yamamoto S; Ito S; Shindo M; Sato K; Kondo T; Kohda K; Sakai H; Mori A; Takahashi T; Ikeda H; Kuroda H; Haseyama Y; Yamamoto M; Sarashina T; Yoshida M; Kobayashi R; Nishio M; Ishihara T; Hirayama Y; Kakinoki Y; Kobayashi H; Fukuhara T; Imamura M; Kurosawa M
Eur J Haematol; 2018 Jul; 101(1):95-105. PubMed ID: 29660177
[TBL] [Abstract][Full Text] [Related]
9. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
[TBL] [Abstract][Full Text] [Related]
10. Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
Markovic U; Bulla A; Leotta S; Stella S; Consoli ML; TambÈ L; Conticello C; DI Raimondo F; Stagno F
Anticancer Res; 2020 Sep; 40(9):5313-5317. PubMed ID: 32878823
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
Jabbour E; Cortes J; Kantarjian H
Cancer; 2011 Mar; 117(5):897-906. PubMed ID: 20945321
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
Smith BD; Brümmendorf TH; Roboz GJ; Gambacorti-Passerini C; Charbonnier A; Viqueira A; Leip E; Purcell S; Goldman EH; Giles F; Ernst T; Hochhaus A; Rosti G
Leuk Res; 2024 Apr; 139():107481. PubMed ID: 38484432
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
Smith BD; Liu J; Latremouille-Viau D; Guerin A; Fernandez D; Chen L
Curr Med Res Opin; 2016 May; 32(5):817-27. PubMed ID: 26743563
[TBL] [Abstract][Full Text] [Related]
14. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Jabbour E; Lipton JH
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
[TBL] [Abstract][Full Text] [Related]
15. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.
Wang R; Cong Y; Li C; Zhang C; Lin H
Medicine (Baltimore); 2019 Apr; 98(15):e15222. PubMed ID: 30985724
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
Tang L; Zhang H; Peng YZ; Li CG; Jiang HW; Xu M; Mei H; Hu Y
BMC Cancer; 2019 Aug; 19(1):849. PubMed ID: 31462241
[TBL] [Abstract][Full Text] [Related]
19. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Wei G; Rafiyath S; Liu D
J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
